NUZ-001, an investigational oral therapy being developed by Neurizon Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS), is officially the ninth compound to be included in the HEALEY ALS platform trial. The announcement follows clearance by the U.S. Food and Drug Administration (FDA) of an amended trial protocol,…
Oral therapy NUZ-001 cleared by FDA to join platform trial for ALS
December is traditionally a cherished time for holiday festivities and reflecting on the year that has passed. This month, I am sending bucketfuls of gratitude to my friends and family for their love and support, and I thank my readers for choosing to spend their time with me. Yet, as…
The U.S. Food and Drug Administration (FDA) has cleared the start of a pivotal Phase 3 clinical trial testing the oral therapy pridopidine in people with amyotrophic lateral sclerosis (ALS). Dubbed PREVAiLS, the trial will assess pridopidine’s efficacy and safety in up to 500 people with early, rapidly progressive ALS,…
Qalsody (tofersen) is one step closer to being covered by public Canadian healthcare systems when used to treat adults with amyotrophic lateral sclerosis (ALS) who carry mutations in the SOD1 gene (SOD1-ALS). Developed by Biogen, the therapy was conditionally approved by Health Canada in March, allowing…
Researchers have developed a novel approach to detect amyotrophic lateral sclerosis (ALS) and predict survival outcomes in patients by measuring genetic activity in blood cells, according to a study. The scientists also built on their genetic activity analysis to define biological pathways that are disrupted in ALS and identify…
My late husband, Jeff, loved holidays. He was a sentimental person hidden within a sometimes gruff exterior, and his sweet side was never more evident than on special occasions. He celebrated Valentine’s Day, birthdays, and Thanksgiving with reverence, making each day meaningful with unique traditions, sumptuous meals he’d made from…
AMX0114, being developed as an amyotrophic lateral sclerosis (ALS) medication, has been well tolerated in early clinical testing, and a second group of patients will now test a higher dose of the experimental treatment. The first group of 12 participants enrolled in the Phase 1 LUMINA clinical trial…
I had a bad cold last week and am still recovering from it. Apart from concern over my husband, Todd, catching it, because he has ALS, the hardest part was trying to keep up with his caregiving when I was fatigued and needed to rest. Something surprised me, though:…
Neurosense Therapeutics is gearing up to submit an application to Health Canada for approval of PrimeC to treat amyotrophic lateral sclerosis (ALS). The company said it had a “productive discussion” with Health Canada, during which the agency confirmed that Neurosense’s proposed next steps align with its expectations. A…
Living with ALS certainly comes with many frustrations. For me, the one that challenges me most is a symptom I can’t hide: slowness. My body simply needs more time to move, eat, and speak than everyone else around me. In a world obsessed with speed — from 10-second commercials…
Recent Posts
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.